<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973115</url>
  </required_header>
  <id_info>
    <org_study_id>HM-SIM-302</org_study_id>
    <nct_id>NCT00973115</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia</brief_title>
  <official_title>Efficacy and Safety of Morning Versus Evening Intake of Simvast CR Tablet in Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of morning versus evening
      intake of Simvastatin Controlled Release tablet 20mg for 8 weeks in patients with
      hyperlipidemia. This study will investigate equivalence of the low-density lipoprotein(LDL)
      cholesterol percent change.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percent change from baseline in LDL cholesterol</measure>
    <time_frame>week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change and the percent change from baseline for total cholesterol, HDL cholesterol, Triglyceride, apolipoprotein A-I, apolipoprotein B, and lipoprotein(a)</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Simvastatin CR 20mg- morning administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin CR 20mg- evening administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin CR</intervention_name>
    <arm_group_label>Simvastatin CR 20mg- morning administration</arm_group_label>
    <arm_group_label>Simvastatin CR 20mg- evening administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 19 and 75

          -  Defined as a fasting 100mg/dl≤ LDL cholesterol &lt;220mg/dl and triglyceride level&lt;400
             mg/dl

          -  Need drug therapy by NCEP ATP III guideline

          -  Signed informed consent

        Exclusion Criteria:

          -  Has a hypersensitivity to HMG-CoA reductase inhibitor or simvastatin

          -  Has a presence or history of alcohol abuse or drug abuse

          -  Active gallbladder disease within 12 months

          -  Pancreatitis or Hepatic dysfunction (ALT or AST levels &gt; 2XUNL)

          -  HbA1c≥ 9% in type 2 diabetes mellitus patients

          -  SBP &lt; 90mmHg or &gt; 160mmHg

          -  DBP &lt; 50mmHg or &gt; 100mmHg

          -  Myocardial infarction or revascularization procedure within 6 months

          -  Has significant cardiovascular disease

          -  Malignant tumor within 5years

          -  Has fibromyalgia, myopathy, rhabdomyolysis or acute myalgia

          -  Uric acid level &gt; 9 mg/dl

          -  Thyroid stimulating hormone ≥ 2XUNL

          -  Active peptic ulcer disease

          -  CPK levels &gt; 3XUNL

          -  creatinine level &gt; 2 mg/dl

          -  Negative pregnancy test for women of childbearing age and agreement to use
             contraception while on study

          -  Had participated other clinical trial within 4 weeks

          -  Need systemic administration of corticosteroids intermittently
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong-Hoon Park, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ehwa Womans University Mokdong Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>8 Sites</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

